Basics of TGF-β and pancreatic cancer

被引:133
|
作者
Truty, Mark J.
Urrutia, Raul
机构
[1] Mayo Clin, Gastrointestinal Res Unit, Rochester, MN 55905 USA
[2] Mayo Clin, Clin Coll Med, Dept Surg, Rochester, MN USA
[3] Mayo Clin, Clin Coll Med, Gastrointestinal Res Unit, Rochester, MN USA
关键词
pancreatic cancer; transforming growth factor-beta; signaling system;
D O I
10.1159/000108959
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Pancreatic cancer is the 4th leading cause of cancer-related death in the United States. The number of diagnoses per year equals the number of deaths per year, making it the deadliest of all malignancies. Modern advances and breakthroughs in molecular oncology have allowed researchers to gain a better understanding of the mechanisms responsible for the pathogenesis of this disease. The transforming growth factor-beta (TGF-beta) pathway is one of the signaling systems that has been identified as a major contributor. TGF-beta plays a paradoxical role as both a tumor suppressor and a tumor promoter in pancreatic cancer. The purpose of this review is to provide the practicing clinician a thorough review of this molecule and its associated signaling partners in the context of its duplicitous role and behavior in patients with pancreatic cancer. Copyright (C) 2007 S. Karger AG, Basel and IAP.
引用
收藏
页码:423 / 435
页数:13
相关论文
共 50 条
  • [41] Correction to: microRNA-193a stimulates pancreatic cancer cell repopulation and metastasis through modulating TGF-β2/TGF-βRIII signalings
    Chi Fang
    Chen-yun Dai
    Zhu Mei
    Ming-jie Jiang
    Dian-na Gu
    Qian Huang
    Ling Tian
    Journal of Experimental & Clinical Cancer Research, 40
  • [42] TGF-β Signal Inhibition With Adenovirus Expressing Soluble TGF-β Receptor II Suppresses Pancreatic Cancer Cell Viability Independent From EMT
    Hoshino, Shigenori
    Vickers, Selwyn M.
    Yamamoto, Masato
    Adachi, Yasuo
    GASTROENTEROLOGY, 2010, 138 (05) : S503 - S503
  • [43] TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma
    Marcus A. Alvarez
    Júlia Pedó Freitas
    S. Mazher Hussain
    Evan S. Glazer
    Journal of Gastrointestinal Cancer, 2019, 50 : 207 - 213
  • [44] TGF- Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma
    Alvarez, Marcus A.
    Freitas, Julia Pedo
    Hussain, S. Mazher
    Glazer, Evan S.
    JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (02) : 207 - 213
  • [45] Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas
    Neuzillet, Cindy
    de Gramont, Armand
    Tijeras-Raballand, Annemilai
    de Mestier, Louis
    Cros, Jerome
    Faivre, Sandrine
    Raymond, Eric
    ONCOTARGET, 2014, 5 (01) : 78 - 94
  • [46] TGF-β inhibitors for the treatment of cancer
    Lahn, M
    Kloeker, S
    Berry, BS
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (06) : 629 - 641
  • [47] From TGF-β to cancer therapy
    Huang, XM
    Lee, C
    CURRENT DRUG TARGETS, 2003, 4 (03) : 243 - 250
  • [48] TGF-β signaling in cancer metastasis
    Xie, Feng
    Ling, Li
    van Dam, Hans
    Zhou, Fangfang
    Zhang, Long
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2018, 50 (01) : 121 - 132
  • [49] Targeting TGF-β signaling in cancer
    Katz, Lior H.
    Li, Ying
    Chen, Jiun-Sheng
    Munoz, Nina M.
    Majumdar, Avijit
    Chen, Jian
    Mishra, Lopa
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (07) : 743 - 760
  • [50] TGF-β signaling in progression of cancer
    Miyazono, Kohei
    CANCER SCIENCE, 2021, 112 : 130 - 130